

## Supplementary material

Supplementary Table S1. Schematic drug reduction schedule in drug reduction group of patients with established RA.

	Baseline DAS28-ESR	6 months DAS28-ESR	Medication modification schedule
<b>Drug reduction group</b>			
Patient 1	2.32	2.81	Adalimumab 40mg biweekly subcutaneous inject -> hold
Patient 2	2.48	2.31	Methotrexate 10mg weekly, Sulfasalazine 500mg bid -> hold
Patient 3	2.5	1.45	Methotrexate 7.5mg weekly -> hold
Patient 4	3.2	2.4	Leflunomide 20mg qd, hydroxychloroquine 200mg qd -> Leflunomide 10mg qd
Patient 5	3.1	2.87	Leflunomide 20mg qd -> Leflunomide 10mg qd
Patient 6	2.95	2.82	Methotrexate 15mg weekly -> Methotrexate 10mg weekly
Patient 7	2.26	2.52	Methotrexate 12.5mg weekly, hydroxychloroquine 200mg qd -> Methotrexate 10mg weekly
Patient 8	2.52	2.61	Golimumab 50mg monthly subcutaneous inject -> Golimumab 50mg every 6 weeks
Patient 9	3.1	3.01	Methotrexate 15mg weekly -> Methotrexate 10mg weekly
Patient 10	2.92	2.83	Tocilizumab 8mg/kg IV monthly -> Tocilizumab 8mg/kg IV every 6 weeks
Patient 11	2.37	2.45	Methotrexate 10mg weekly + Infliximab 3mg/kg IV bimonthly -> Methotrexate 10mg weekly
Patient 12	2.03	1.94	Adalimumab 40mg biweekly subcutaneous inject -> Adalimumab 40mg every 3 weeks inject
Patient 13	2.48	2.55	Methotrexate 12.5mg weekly, sulfasalazine 1000mg bid -> Methotrexate 10mg weekly
Patient 14	3.15	3.02	Sulfasalazine 500mg bid, hydroxychloroquine 200mg qd -> hydroxychloroquine 200mg qd
<b>Drug maintenance / relapse after drug reduction group</b>			
Patient 1	3.04	4.52	Methotrexate 15mg weekly, sulfasalazine 1000mg bid -> Methotrexate 10mg weekly (Relapse)
Patient 2	2.59	5.24	Methotrexate 15mg weekly, hydroxychloroquine 200mg qd -> Methotrexate 10mg weekly, hydroxychloroquine 200mg qd (Relapse)
Patient 3	2.72	3.91	Adalimumab 40mg biweekly subcutaneous inject -> Adalimumab 40mg every 3 weeks (Relapse)
Patient 4	2.61	3.12	Methotrexate 12.5mg weekly, hydroxychloroquine 200mg qd (Maintenance)
Patient 5	2.78	2.99	Leflunomide 20mg qd (Maintenance)
Patient 6	2.73	2.91	Leflunomide 20mg qd, hydroxychloroquine 200mg qd (Maintenance)
Patient 7	3.09	3.21	Methotrexate 10mg weekly, sulfasalazine 500mg bid (Maintenance)
Patient 8	2.78	2.89	Methotrexate 10mg weekly (Maintenance)
Patient 9	2.66	3.02	Methotrexate 15mg weekly, hydroxychloroquine 200mg qd (Maintenance)
Patient 10	3.1	3.45	Tofacitinib 5mg bid (Maintenance)
Patient 11	2.85	3.32	Tofacitinib 5mg bid (Maintenance)
Patient 12	2.95	3.44	Methotrexate 12.5mg weekly, hydroxychloroquine 200mg qd (Maintenance)
Patient 13	2.95	2.99	Methotrexate 10mg weekly (Maintenance)
Patient 14	3.11	3.21	Tofacitinib 5mg bid (Maintenance)
Patient 15	2.89	3.32	Methotrexate 12.5mg weekly, Leflunomide 20mg qd (Maintenance)
Patient 16	2.56	2.94	Leflunomide 20mg qd, sulfasalazine 500mg bid (Maintenance)
Patient 17	2.47	2.52	Methotrexate 10mg weekly (Maintenance)
Patient 18	3.14	3.18	Methotrexate 12.5mg weekly, hydroxychloroquine 200mg qd (Maintenance)
Patient 19	3.14	3.11	Tofacitinib 5mg bid (Maintenance)
Patient 20	2.95	2.99	Methotrexate 15mg weekly (Maintenance)

## Supplementary Fig. S1.

Flow chart of established RA.

